secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLOBUS MEDICAL INC (GMED)
CIK:        0001237831
Form:       8-K
Filed at:   2025-02-20T23:59:59+00:00
Accession:  0001562762-25-000024
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Globus Medical Q4 sales $657.3M (+6.6% YoY); guides 2025 with Nevro acquisition impact
--------------------------------------------------------------------------------

- Q4 net sales $657.3M (+6.6% as-reported, +6.9% constant currency); GAAP EPS $0.19, non-GAAP EPS $0.84.
- Full-year 2024 net sales $2,519.4M (+60.6% YoY); GAAP net income $103.0M; GAAP EPS $0.75, non-GAAP EPS $3.04.
- 2025 stand-alone guidance: revenue $2.66-2.69B, non-GAAP EPS $3.40-3.50; with Nevro acquisition (close late Q2): revenue $2.80-2.90B, non-GAAP EPS $3.10-3.40.
- Q4 non-GAAP adjusted EBITDA $196.9M (30.0% of sales); full-year operating cash flow $520.6M, free cash flow $405.2M.
- CEO cites record product launches and integration progress; team executed on strategic objectives to drive value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1237831/000156276225000024/0001562762-25-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1237831/000156276225000024/gmed-20250220x8k.htm
  HTML page:      https://secwatch.observer/filing/0001562762-25-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer